Enorama Pharma AB Cash Flow Conversion Efficiency
Enorama Pharma AB cash flow conversion efficiency. Based on the latest financial reports, Enorama Pharma AB (ERMA) has a cash flow conversion efficiency ratio of 0.297x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-14.97 Million ≈ $-1.61 Million USD) by net assets (Skr-50.44 Million ≈ $-5.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Enorama Pharma AB (2014–2025)
Cash flow conversion efficiency of Enorama Pharma AB from 2014 to 2025. This chart illustrates how Enorama Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Enorama Pharma AB stock price today for real-time trading data and today's change.
Enorama Pharma AB Cash Flow Conversion Ratio Explained
Enorama Pharma AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Enorama Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enorama Pharma AB ranked by their cash flow conversion efficiency. Also see market value of Enorama Pharma AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WISDOM ED.INTL.HLD.HD-01
F:5Q4
|
N/A |
|
Sharc International Systems
F:IWIA
|
0.409x |
|
Mexican Gold Corp
V:MEX
|
0.953x |
|
ODIGMA CONSULTANCY SOLUTIONS LTD
NSE:ODIGMA
|
N/A |
|
Slam Exploration Ltd.
V:SXL
|
-0.046x |
|
IL&FS Transportation Networks Limited
NSE:IL&FSTRANS
|
0.000x |
|
Puri Global Sukses Tbk Pt
JK:PURI
|
-0.151x |
|
FG Financial Group
NASDAQ:FGF
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Enorama Pharma AB (2014–2025)
The table below shows the annual cash flow conversion efficiency of Enorama Pharma AB from 2014 to 2025. Review ERMA cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-23.45 Million ≈ $-2.52 Million |
Skr-59.26 Million ≈ $-6.38 Million |
2.527x | +155.23% |
| 2024-12-31 | Skr7.80 Million ≈ $839.73K |
Skr-35.70 Million ≈ $-3.84 Million |
-4.575x | -116.20% |
| 2023-12-31 | Skr19.54 Million ≈ $2.10 Million |
Skr-41.35 Million ≈ $-4.45 Million |
-2.116x | -102.43% |
| 2022-12-31 | Skr31.52 Million ≈ $3.39 Million |
Skr-32.96 Million ≈ $-3.55 Million |
-1.045x | +25.99% |
| 2021-12-31 | Skr21.35 Million ≈ $2.30 Million |
Skr-30.16 Million ≈ $-3.25 Million |
-1.413x | +89.09% |
| 2020-12-31 | Skr1.78 Million ≈ $191.23K |
Skr-23.00 Million ≈ $-2.47 Million |
-12.942x | -249.80% |
| 2019-12-31 | Skr7.18 Million ≈ $772.64K |
Skr-26.56 Million ≈ $-2.86 Million |
-3.700x | -371.31% |
| 2018-12-31 | Skr17.02 Million ≈ $1.83 Million |
Skr-13.36 Million ≈ $-1.44 Million |
-0.785x | +13.32% |
| 2017-12-31 | Skr7.36 Million ≈ $792.18K |
Skr-6.67 Million ≈ $-717.43K |
-0.906x | -34.48% |
| 2016-12-31 | Skr9.08 Million ≈ $977.10K |
Skr-6.11 Million ≈ $-658.02K |
-0.673x | -1015.31% |
| 2015-12-31 | Skr6.52 Million ≈ $702.09K |
Skr480.00K ≈ $51.66K |
0.074x | -36.25% |
| 2014-12-31 | Skr2.66 Million ≈ $286.26K |
Skr307.00K ≈ $33.04K |
0.115x | -- |
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells tobacco-free white snus in Sweden. It offers its products under the NIC-S brand name. The company was incorporated in 2006 and is based in Stockholm, Sweden.